MUSTANG BIO, INC. - Common Stock, $0.0001 Par Value (MBIO)

CUSIP: 62818Q302

Q2 2026 13F Holders as of 30 Jun 2026

Security type / class
Equity / Common Stock, $0.0001 Par Value
Total 13F shares
197,516
Total 13F value
$138,656
Holder snapshot 5 signals
Share change
+20,949
SEC-reported price per share
$0.70
Number of holders
4
Value change
+$14,706
Number of buys
1
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
6,715,538

Security key

62818Q302

Report period

Q2 2026

Institutions

4

Top holders

4

MBIO full security history Ownership snapshot Full 13F holder table Previous quarter: Q1 2026 MUSTANG BIO, INC. SEC filings MUSTANG BIO, INC. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of MBIO - MUSTANG BIO, INC. - Common Stock, $0.0001 Par Value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Fortress Biotech, Inc.
Disclosed value leader
Fortress Biotech, Inc.
Comparable rows
15/15
Latest evidence
24 Apr 2026
13D/G 3/4/5 13F Lead comparable stake: 8% 13D/G row: Fortress Biotech, Inc. Showing 1-6 of 15 holder rows.

Quick read

Fortress Biotech, Inc. leads the comparable SEC ownership view at 8%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Fortress Biotech, Inc.'s linked filing trail.
Comparable ownership Top 5
Fortress Biotech, Inc. 8%
INTRACOASTAL CAPITAL, LLC 5%
ARMISTICE CAPITAL, LLC 5%
Manuel Litchman MD 0.02%
Adam J. Chill 0.01%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Fortress Biotech, Inc.
13D/G 3/4/5
10%+ Owner
13D/G 3/4/5
8%
$698,416
537,243 shares
 +$361,900 02 Jan 2026
INTRACOASTAL CAPITAL, LLC
13D/G
Mitchell P. Kopin
13D/G
5%
$491,647
185,527 shares
 -$134,951 30 Jun 2025
ARMISTICE CAPITAL, LLC
13D/G
13D/G
5%
$149,887
129,213 shares
 -$5,773,406 31 Mar 2025
Manuel Litchman MD
3/4/5
President, CEO and Interim CFO, Director
3/4/5
0.02%
$1,076
1,615 shares
 — 24 Apr 2026
Adam J. Chill
3/4/5
Director
3/4/5
0.01%
$358
375 shares
 -$4 30 Dec 2025
David Jin
3/4/5
Director
3/4/5
0%
$275
286 shares
 +$238 30 Dec 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
4
Shares
197,516
Rows available
4
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2026 vs Q1 2026 Across Filers

Q1 2026 holders
22
Q2 2026 holders
4
Holder diff
-18
Investor Q1 2026 Shares Q2 2026 Shares Share Diff Share Chg % Q1 2026 value Q2 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .